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Monoclonal gammopathy of undetermined significance (MGUS) is a clonal plasma cell disorder implicated as a precursor of multiple 
myeloma (MM), while smoldering multiple myeloma (SMM) is a malignant plasma cell disorder without evidence of a myeloma-defining 
event(s) (MDE). This is a review article of both disorders outlining their current definition and management according to the current 
standard of care. We focus on the pathogenesis of MM and the role of MGUS and SMM in the development of active MM. MGUS is 
a benign disorder and, subsequently, is followed by observation. In contrast, for SMM, although the current standard of care is “watch 
and wait”, this paper will explore the circumstances in which treatment should be considered to prevent MDE.
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Introduction
Monoclonal gammopathies are a group of disorders with altered 
immunological homeostasis and the presence of abnormal monoclonal 
protein in the blood and/or urine. These proteins may have no immediate 
or long-term clinical significance or can be associated with clinical 
relevance such as monoclonal gammopathy of renal significance 
(MGRS), paraneoplastic syndromes (e.g., neuropathy) or evolution 
into malignant clonal diseases (MM, AL amyloidosis, Waldenström’s 
macroglobulinemia, chronic lymphocytic leukemia, and non-Hodgkin’s 
lymphoma). The condition of benign monoclonal gammopathy was 
first described in 1978 by Dr Kyle in 241 asymptomatic patients with 
evidence of monoclonal protein in the serum, yet no evidence of MM, AL 
amyloidosis, or Waldenström’s macroglobulinemia at the time of diagnosis 
[1, 2]. Ultimately, the term was changed to monoclonal gammopathy of 
undetermined significance (MGUS) [3]. Smoldering multiple myeloma 
(SMM), a disorder first coined in 1980, described six patients with 10% 
or more plasma in the bone marrow (BM) and no evidence of end-
organ dysfunction at diagnosis; however, with a potential of malignant 
transformation to MM, it was defined as asymptomatic multiple myeloma 
(AMM) [4]. SMM includes a broad spectrum of patients from low to a high 
risk of development of end-organ damage defining MM [5].
The definitions of multiple myeloma (MM), SMM, and MGUS, with 
detailed diagnostic criteria are presented in table I [6].
Multiple myeloma
MM is usually a progressive plasma cells (PCs) malignancy leading 
to end-stage organ disease with significant morbidity and subsequent 
mortality. It is diagnosed based on the International Myeloma Working 
Group (IMWG) criteria updated in 2014 [7], including the presence 
of clonal BM PCs ≥10% confirmed via trephine biopsy or biopsy-
proven solitary bony or extramedullary plasmacytoma and at least 
one myeloma-defining event(s) (MDE). Prior to 2014, the end-organ 
destruction was classified under the acronym CRAB. However, in 
the newest criteria it has evolved into MDEs, updated to SLiM CRAB 
acronym, which identifies the following MM symptoms:
C (calcium) – hypercalcemia: serum calcium >0.25 mmol/L 
(>1 mg/dL) higher than the upper limit of normal or >2.75 mmol/L 
(>11 mg/dL);
R (renal insufficiency) – creatinine clearance <40 mL/min or 
serum creatinine >177 mmol/L (>2 mg/dL);
A (anemia) – hemoglobin value of >20 g/L below the lower limit of 
normal, or a hemoglobin value <100 g/L;
B (bone lesions) – at least osteolytic lesions on skeletal radiography, 
computed tomography (CT), or fusion 18F-fluorodeoxyglucose 
positron-emission tomography (18F-FDGPET/CT);
as well as the following biomarkers of malignancy:
S (sixty) – clonal BM PC percentage (60%) with clonality 
established by showing kappa/lambda light-chain restriction on 
flow cytometry, immunohistochemistry, or immunofluorescence;
Li (light chains) – involved to uninvolved serum-free light chain 
ratio > 100 (measured in the serum Freelite assay);
M (magnetic resonance) – more than one focal lesion on magnetic 
resonance imaging studies, each of them at least 5 mm in size.
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The diagnostic criteria were updated to identify the group of patients 
who would have been previously diagnosed with SMM, but who have 
biomarkers that almost always predetermined the development of 
CRAB features. This would prolong the inevitable diagnosis of MM 
and significantly delay the implementation of treatment.
MM is the second most common blood malignancy following 
lymphoma with an estimated 32,110 new diagnoses and 12,960 
deaths in 2019 in the United States, which was roughly 1.8% of 
all new cancer cases in the United States [8]. Most commonly, the 
median age of MM at diagnoses is 69–70 years; only 2% of patients 
are <40 years and 38% >70 years [9, 10].
The prognosis has vitally improved in recent years; the overall 
survival (OS) was only 1 year prior to the introduction of alkylating 
agents in the 1950s to a median of 5.5 years in the 2000s [11]. This 
improvement in survival is due to the introduction of target therapy 
(proteasome inhibitors, immunomodulatory agents, and monoclonal 
antibodies) and the incorporation of high-dose chemotherapy with 
autologous stem cell transplants [12, 13].
Despite the growing improvements in treatment and survival, 
MM remains an incurable disease; therefore, increasing survival, 
improving quality of life, and researching its evolution are the relevant 
goals of ongoing research [14].
Pathogenesis and role of premalignant conditions in the 
development of MM
MM is a disease characterized by uncontrolled growth and 
proliferation of malignant PCs. The pathogenesis remains poorly 
understood. Numerous risk factors have been implicated; however, 
a specific cause/effect has yet to be elucidated. An epidemiologic 
study carried out by Alexander et al. [15] confirmed that incidence 
rates increase with age, particularly after age 50, and are higher in 
men, particularly African American men. Although relatively low, there 
is an increased propensity for the development of MM and other 
B-cell malignancies in families. Although a variety of autoimmune 
diseases have been implicated as increasing the risk of development 
of MM, only pernicious anemia and ankylosing spondylitis have been 
associated with an increased risk [16]. Many environmental factors, 
such as ionizing radiation, exposure to benzenes, and petroleum 
as well as smoke and other industrial and agricultural toxins, were 
hypothesized to contribute to the pathogenesis [16, 17]. The US 
government recognizes three potential risk groups: troops exposed 
to Agent Orange during the Vietnam War period, extensively exposed 
workers after 9/11, and troops who served at Camp Lejeune, North 
Carolina. As mentioned, MGUS is a precursor of MM. In a study 
conducted by Landgren et al. [17], they found that almost all MM 
cases studied had a preceding incidence of MGUS [17, 18, 19]. 
Similar findings have been described in studies carried out by the 
Mayo Clinic in the group of United States veterans, thus highlighting 
the pivotal role of MGUS in the pathogenesis of MM [18, 19]. There 
is increasing data to support the concept of intraclonal heterogeneity 
and the existence of simultaneous multiple clones of tumor cells at 
the time of diagnosis [20–25]. This was demonstrated for MM by 
Morgan et al. [24] and Keats et al. [26], describing clonal evolution 
from MGUS to MM and plasma cell leukemia (PCL). As this theory 
is likely to be a part of the natural progression of MM, it also serves 
to emphasize a potential target for treatment or the need to initiate 
treatment in the early stages of this heterogeneity, for instance, 
MGUS [13, 22, 24, 25–28].
Although MM is thought to evolve in this sequence, its propagation is 
a result of a multitude of factors: inherited genetic variation, myeloma 
cell gene mutations, deletions, and amplifications which occur 
throughout the natural history of the disease [29, 30, 31]. Another 
crucial factor in the translation of PCs to MM is the impact of the BM 
microenvironment. This had an implication in the clinical trials focused 
on altering the microenvironment, with some potential treatment 
targets revealed [21, 32, 33]. It is now largely acknowledged that 
the progression of myeloma is as a result of immune dysregulation 
and loss of immune system surveillance. For instance, the BM 
microenvironment in MM has been shown to create a protected area 
for tumor cells through the secretion of growth factors and cytokines 
and via upregulation of inhibitory receptor/ligand pairs such as 
programmed death receptor-1/programmed death ligand (PD-1/PD-
L1). Furthermore, increased numbers of circulating myeloid-derived 
suppressor cells and the inhibition of effective antigen presentation 
by dendritic cells, coupled with the loss of regulatory T cells and 
TH17 cells from the T-cell reserve, are all components believed to 
contribute to propagation of MM cells, their proliferation, and disease 
progression [34–38].
Monoclonal gammopathy of undetermined 
significance
MGUS is a premalignant PC disorder. The more prevalent type, 
non-IgM MGUS, generally originates from mature PCs that have 
had switch recombination and may lead to MM [31, 39]. The specific 
diagnostic criteria for MGUS defined by the IMWG are presented in 
table I [40].
Table I. Criteria for diagnosis of MGUS, smoldering MM, and MM
MGUS Smoldering MM Multiple myeloma
Serum M protein <3g/dL assessed in 
electrophoresis and immunofixation
Serum monoclonal protein (IgG/IgA)≥3g/dL or 
urinary monoclonal protein ≥500 mg per 24 h
M protein present (IIMM, LCMM) or absent (NSMM) – 
not required for the diagnosis
Clonal bone marrow plasma cells <10% in the 
trephine biopsy
Clonal bone marrow plasma cells 10%–60% in the 
trephine biopsy
Clonal bone marrow plasma cells ≥10% in the 
trephine biopsy 
Absence of end-organ damage (no CRAB features) 
and amyloidosis
Absence of myeloma-defining events or 
amyloidosis
Myeloma-defining events
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Prevalence
Population-based studies have demonstrated that the production of 
MGUS can begin as young as 30 years of age; however, accurate 
percentages are not available. MGUS was found in approximately 
3% of people aged ≥50 years and roughly 5% of people ≥70 years 
[41–45]. The prevalence of MM is twofold higher in the African 
American populations, which is due to a higher incidence of MGUS, 
thought to be due to the initial pathogenesis beginning at an earlier 
age [44].
Progression of MGUS to MM
The risk of progression to MM has been demonstrated by Kyle et 
al. to increase cumulatively by 1.5% per year [40, 41, 46]. The risk 
of progression can be estimated based on defined risk factors; the 
most definitive of these are the concentration of M protein > 1.5 g/dl, 
immunoglobulin isotype (non-IgG), and abnormal serum-free light 
chain (sFLC) ratio [40, 47]. Focusing on non-IgM MGUS patients, the 
projected risk at 20 years is 30% if they possess two risk factors, 20% 
for those with only one risk factor, and 7% for those who possess no 
risk factors (Tab. II) [39].
The immunoglobulin isotype is also a key indicator of risk. Patients 
with IgM or IgA monoclonal proteins are at higher risk of progression 
in contrast to those with IgG monoclonal protein. The risk of 
progression among patients with IgM MGUS is nearly 11 times that 
of a normal, comparable population [48]. Similarly, the percentage of 
BM PCs is of significance in risk assessment. In a study by Cesana et 
al. [49], they observed that MGUS patients with greater than 5% BM 
PCs were at greater risk of malignant transformation. Further studies 
by this group demonstrated that the evolution of the disease was just 
6.8% when the BM PCs were less than 10% while it was significantly 
greater at 37% in patients with BM PCs at 10%–30% [50]. The IMWG 
concluded that patients with ≥10% PCs are considered to have SMM 
or MM [40]. Additionally, serum-free light chain ratios have prognostic 
value in MGUS. Rajkumar et al. [51] reported that 382/1,148 patients 
with aberrant FLC ratios at diagnosis demonstrated a higher risk 
of progression to myeloma compared to those with normal serum-
free light chain ratios. Recent studies by Landgren et al. [52] further 
highlight these prognostic factors in the acceleration of MGUS to MM. 
They found that changes in the immune marker values varied over 
time. They studied 685 MGUS patients of which 187 progressed from 
MGUS to MM and some from light chain MGUS to light chain MM. 
By analyzing the M spike concentration and serum FLC for each patient 
sample, they found that they were both increased and correlated with 
a higher risk of MM. The high-risk score was evident in the serum for 
up to 5 years before the diagnosis of the MM, thus highlighting the 
biomarkers that can predict MGUS progression and the potential for 
the treatment of high-risk MGUS before disease in and, further, the 
importance of constant follow-up in MGUS patients [52, 53].
Management of MGUS
Traditionally, the management of MGUS has been a “watch and wait” 
strategy. MGUS patients are monitored, as recommended above, 
for progression to MM; the frequency of the recommended serial 
evaluations is described below.
MGUS with low risk of progression
If the serum monoclonal protein is <15 g/L, IgG type, and the FLC 
ratio is normal, the risk of eventual progression to myeloma or 
related malignancy is low. In these patients, complete blood count, 
creatinine, and calcium values are usually indicative of MGUS and 
should be evaluated regularly. A BM examination or radiography is 
not routine; however, if a patient presents with renal insufficiency, 
hypercalcemia, bone lesions, or unexplained anemia, a BM aspiration 
would be required. These patients should have their serum protein 
electrophoresis in 6 months, and if this is not indicative, they can be 
followed up every 2–3 years [40, 41, 54].
MGUS with intermediate and high risk of progression
If an MGUS patient has a serum monoclonal protein >15 g/L, IgA 
or IgM protein type, or an abnormal FLC ratio, a BM aspirate and 
biopsy should be done to rule out an MM or another PC malignancy. 
BM needs to be evaluated by both conventional cytogenetics and 
fluorescence in situ hybridization (FISH) [40, 41, 54].
Implications of MGUS and roles for potential treatments
Whereas the standard of care for MGUS is observation, recent 
clinical trials support the concept that early treatment initiation may 
improve survival and decrease the risk of an MDE [55].
Melton et al. [56] described the prevalence of osteoporosis and 
fractures among MGUS patients. They were greater than in the 
Table II. Risk stratification for progression of monoclonal gammopathy of undetermined significance to multiple myeloma
Risk group No. of patients Relative risk Absolute risk of progression at 20 years (%)
Absoluter risk of progression at 
20 years accounting for death as a 
competing risk (%)
Low-risk (serum M protein <1.5 g/dL, IgG subtype, 
normal FLC ratio (0.26–1.65)
449 1 5 2
Low-intermediate-risk (any one factor abnormal) 420 5.4 21 10
High-intermediate -risk (any two factors abnormal) 226 10.1 37 18
High-risk (all three factors abnormal) 53 20.8 58 27
Adapted from Monoclonal gammopathy of undetermined significance and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspective risk factors for progression and 
guidelines for monitoring and management [40]
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general population of age-matched controls. Further research 
demonstrated the increased incidence of fractures, in particular of 
the hip and vertebral column, in addition to greater osteoporosis 
and hypercalcemia [57, 58]. This highlights a potential proactive 
role of bisphosphonates or rank-ligand inhibitors as well as calcium/
vitamin D supplementation in MGUS patients, as has been routinely 
incorporated into the management of osteoporosis [59].
Although there is no specific treatment for MGUS, it has been shown 
to reduce life expectancy even when a malignant transformation is not 
present. MGUS patients have decreased survival from a diagnosis of 
8.1 years in comparison to 12.4 years for matched controls [39, 60, 
61]. Additionally, MGUS patients have been shown to have numerous 
complications and associated comorbidities, including MGRS, bone 
fractures, peripheral neuropathy, cardiovascular diseases, and 
immunodeficiency [57].
Patients with impaired immune system are two to three times more 
likely to develop bacterial and viral infections [58]. In several studies 
on survival in MGUS, infections have shown to have a standard 
mortality ratio (SMR) of between 1.5 and 2, and with pneumonia, 
sepsis, pyelonephritis, and tuberculosis as the most common causes 
of death [62, 63]. This is likely to be due to impairment of both innate 
and adaptive immunity and, in particular, a reduction in the number of 
NK cells, CD 19+ cells, as well as the blood immunoglobulin level [64]. 
This would seem to highlight the importance of encouraging MGUS 
patients to have herpes zoster vaccinations following the Centers for 
Disease Control and Prevention guidelines for routine vaccinations.
Similar to MM, which is often associated with renal involvement, 
MGUS has also been implicated in renal disease. The term MGRS 
was first coined by the International Kidney and Monoclonal 
Gammopathy Research Group in 2012. It is a heterogeneous 
spectrum of renal diseases that culminate as a result of the 
aggregation of deposited monoclonal immunoglobulin in the kidney 
[65]. Generally, patients are found to have unidentified deterioration 
of renal function and proteinuria, which may result in renal failure 
[60]. These disorders occur as a result of clonal B-cell proliferation 
with monoclonal antibody production and associated with potential 
capability of complement deregulation [47, 61]. Treatment is 
indicated in these disorders to prevent from further deposition of 
monoclonal immunoglobulins in the tubules and glomeruli, leading 
to irreversible damage and complications of end-stage renal failure. 
Therapy should be modeled after the treatment paradigms for MM 
targeting the clonal PCs producing the immunoglobulins with the goal 
of improving/maintaining renal function [60].
Recommendations
Currently, a population study is being carried out in Iceland called 
iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma). 
This study aims to assess the blood of 140,000 adults aged > 40 in 
Iceland to assess the first signs of MM. Simultaneously, the study is 
looking into particular areas in Iceland where MM cases are known to 
be higher, to try to identify risks associated with the development of the 
disease. The results of this study will no doubt implicate precursors of 
myeloma such as MGUS and potentially identify a greater rationale 
for treatment [66]. In light of the issues mentioned above and the risk 
of malignant transformation associated with high-risk MGUS, clinical 
trials utilizing anti-myeloma therapeutic approaches are actively 
enrolling patients to prevent MDE to improve the future quality of life 
for these patients. One such example is a Phase II clinical trial utilizing 
the anti-CD38 monoclonal antibody daratumumab in patients with 
high-risk MGUS and low-risk SMM. Another study is assessing the 
anti-inflammatory properties of celecoxib in MGUS and SMM patients 
in preventing the development of MM [2]. A search of the clinicltrials.
gov database shows that there are 10 active trials of therapeutic 
intervention in MGUS with an additional 11 recently completed. The 
results of these studies, among others, may be pivotal in redefining 
MGUS and its management in the not so distant future.
Smoldering multiple myeloma
Definition
SMM is synonymous with asymptomatic MM (AMM). It is 
characterized by at least 10% clonal PCs and/or at least 3 g/dL of 
monoclonal protein level. These patients are without any evidence of 
end-organ destruction (no CRAB end-organ damage: hypercalcemia, 
renal insufficiency, anemia, lytic bone disease). The specific 
diagnostic criteria for SMM, defined by the IMWG are presented in 
table I [40].
Prevalence
The median age of incidence is similar to that of MM from 69 to 70 years 
of age [41, 67, 68]. The incidence of SMM is estimated to be between 
10% and 15% of MM patients. Extrapolating from a population study 
by Ravindran et al., it is believed to have an occurrence rate of 0.9 
per 100,000, which corresponds to approximately 4,400 new cases 
of SMM in the United States in 2019 [8, 69, 70].
Progression and risk factors
The risk of progression to symptomatic disease or MM differs from 
that of MGUS; Kyle et al. projected the risk of 10% per year for 
the first 5 years following diagnosis, decreasing to 3% for the next 
5 years and finally 1% in the years following to the 10th year [67, 68]. 
Given these figures the probability of advancement to symptomatic 
disease was 51% at 5 years, 66% at 10 years, and 73% at 15 years 
[40, 71]. The prognostic factors associated with the greatest risk of 
evolution of SMM to MM are dependent on BM plasmacytosis and 
the serum monoclonal protein level at diagnosis [71].
In 2014, the IMWG redefined the criteria for MM diagnosis. They 
included new laboratory and imaging markers. This allowed for the 
identification of high-risk SMM patients who were most at risk of 
progression and, more importantly, in need of treatment to prevent 
end-organ damage (80% at 2 years likelihood of an MDE). The 
markers that were included in the new criteria were BM PC infiltration 
of 60% or greater, an sFLC ratio of ≥100 (or <0.01), or at least 
one focal lesion on cross-sectional imaging of the whole body by 
magnetic resonance imaging (MRI) – now termed in acronym SLiM 
(BM percentage – 60, light chain ratio, MRI) criteria. These criteria 
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highlight biological as well as radiographic findings associated with 
an increased risk of development of an MDE. The new definition 
included patients with high-risk SMM into the treated group, since 
earlier these patients were followed only by observation [7, 72].
How to identify high-risk SMM in the remaining patients
There are several models on how to predict the risk of progression 
in SMM; the most widely accepted models from the Mayo Clinic and 
PETHEMA are presented in table III [73].
The Mayo Clinic model
This model uses serum M protein, BM plasmacytosis, and the sFLC 
ratio. Their study, which was carried out on 273 SMM patients, found 
that an sFLC ratio of >8, a serum M protein level of ≥3 g/dL, or BM 
PCs of ≥10% lead to a 76% risk of progression in 5 years. Likewise, 
the progression risk for patients with two risk factors or “intermediate 
risk” was 51% and 25% if only one risk factor was possessed [74].
The PETHEMA model
This model quantifies aberrant BM PCs by use of flow cytometry. 
Using flow cytometry, the group was able to distinguish the number of 
neoplastic cells and normal PCs using surface markers. They found 
that 95% or greater aberrant BM PCs correlated to a higher risk of 
progression in SMM patients. In addition, there was immunoparesis, 
which is defined by a decrease below the lower limit of normal in one 
or two of non-involved immunoglobulins. This model predicts that 
patients with both aberrant PCs and immunoparesis have a risk of 
progression of 72% within 5 years, patients with one risk factor have an 
intermediate risk of 46% of progression in the same time, and finally, 
none of these factors would have a 4% chance of progression [75, 76].
Genetic models
Neben et al. [77] analyzed chromosomal alterations by FISH. This 
group found that previously proven high-risk aberrations for MM 
had implications in SMM, del(17p13), and t(4;14) and +1q21 leads 
to poor prognosis, time to progression (TTP), and requirement of 
treatment in SMM. The highest risk was associated with del(17p13) 
[77, 78]. Another study using human genome analysis in multiple 
arrays using the GEP-70 score (a genomic assay for prediction of 
event-free and OS in asymptomatic, newly diagnosed, and relapsed 
MM) in addition to the proliferation index may accurately reflect the 
malignant potential of the tumor cells. These findings, which correlate 
high-risk MM with high risk of progression in progenitor diseases, 
highlight how understanding the biology of high-risk MM may be the 
key to disease prevention [79, 80].
Radiographic models
Newer imaging techniques such as MRI and PET/CT can detect 
the myeloma-defining phenomenon significantly earlier than plain 
radiographs. While CT and plain radiographs can detect lytic bone 
lesions in the bone, MRI can assess the BM, therefore demonstrating 
certain growth patterns and may identify disease in its early stage 
[31]. In a large study using MRI for diagnosis of MM, focal lesions 
were noted in 74% of patients using MRI versus 56% of patients with 
skeletal surveys [33, 73]. Furthermore, Hillengass et al. [81] reported 
in a study of 544 SMM patients that MRI found that at least 30% 
of patients had BM manifestations of myeloma similar to that seen 
in MM. In SMM patients, the presence of bone lesions on MRI has 
shown to significantly increase their TTP [82]. A study by Wang et 
al. [82] found that TTP could be as little 1.5 years in patients with 
abnormal MRI in comparison to 5 years when the MRI was normal. 
Hillengass et al. [83] also identified that 28% of SMM patients had 
focal lesions not detected with routine radiographs; even a single 
lesion was predictive for disease progression.
Like MRI, FDG-PET/CT is important, as FDG-PET uptake can show 
focal FDG avid disease while CT demonstrates bone damage. 
This imaging may play a potential role in evaluating the treatment 
response in patients [84, 85]. Although PET/CT has low sensitivity 
for early precursors of the disease, a positive result in SMM is an 
important marker. Conversely, a negative PET/CT in MGUS has 
a high specificity and, thus, could be used for assessment of the 
prognostic risk in the future.
20 February 2020 model
In addition to the different models presented above, a new criteria 
for identification of a high-risk SMM subgroup have been proposed. 
Lakshman et al. [5] described a higher risk of progression in 400 
SMM patients with BM PC%>20%, M-protein>2 g/dL, and FLC ratio 
> 20 to be predictive for risk of progression: the risk of an MDE 
was 46% at 2 years. Further supporting this model, a Phase III 
study was completed by the Eastern Cooperative Oncology Group 
(ECOG; E306) in 182 SMM patients. Patients were randomized to 
lenalidomide and observation groups [86]. The primary endpoint was 
progression-free survival (PFS). They reported that at 35 months 
there was a 72% reduction in the risk of progression to symptomatic 
disease in the lenalidomide group. When comparing the two groups, 
they found that PFS at 1, 2, and 3 years in the treatment arm was 
98%, 93%, and 91% in the lenalidomide arm, in comparison to 
89%, 75%, and 66% in the observation arm. They concluded that 
patients with high-risk SMM using the 20 February 20 model were 
candidates for early treatment with lenalidomide [87]. Despite this, 
there were several faults noted with this study. Biran et al. [88] noted 
that only 56 of the patients were high-risk defined by the Mayo 2018 
criteria and, subsequently, out of these 56 high-risk patients, 31 were 
randomized to the observation arm. Furthermore, these patients 
Table III. Smoldering multiple myeloma risk models
Model Main variants Risk factors
Mayo Serum M protein, BM 
Plasmacytosis, sFLC ratio 
M protein level>3 g/dL, 
plasmacytosis>10%,  
sFLC ratio < 8
PETHEMA Multiparametric flow 
cytometry, serum 
immunoglobulins 
>95% aberrant plasma cells 
and immunoparesis 
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were only followed for a median of 35 months. Moreover, nearly half 
of the patients (47.2%) had aberrant findings on MRI when enrolled, 
which may suggest that these patients had symptomatic MM at the 
time of randomization. The studies’ primary endpoint of PFS is not 
an accurate marker in a disease with no current cure available. 
Therefore, it would be more factual to state that time-to-myeloma is 
delayed rather than prolonged survival. Finally, the question of why 
would one treat a myeloma patient with single-agent lenalidomide, 
when essentially all studies show that triplets, or even quadruplets, 
are superior to doublets in frontline myeloma therapy [88]. As noted 
previously, and by the authors of this article, clonal evolution is a 
pivotal process in the development of MM, thus a single-agent 
treatment is unlikely to target clonal heterogeneity.
Management
All patients suspected of SMM should have the following diagnostic 
and baseline screening tests:
•	 	 Complete blood count;
•	 	 Chemistry profile with measurement of calcium, creatinine, 
albumin, beta-2 microglobulin, and LDH;
•	 	 Quantitative immunoglobulins, serum protein electrophoresis, 
serum immunofixation electrophoresis, and sFLC assay;
•	 	 24-h urine collection for total urine protein, urine protein 
electrophoresis, and urine immunofixation electrophoresis;
•	 	 A baseline BM biopsy for cytogenetics, FISH can be done, 
however, it is not routinely preformed in SMM;
•	 	 A skeletal survey, including low-dose whole-body CT, PET-CT, 
or MRI of the whole-body or spine [7].
The IMWG recommends all the tests mentioned above, initially and 
at follow-up 2–3 months after the diagnosis. While an MRI is not 
mandatory, a BM biopsy and skeletal survey are recommended. 
Paraprotein parameters should be repeated every 4–6 months for 
at least 1 year and, if they remain stable, intervals can be increased 
to every 6–12 months [40, 72]. Depending on the results and risk 
stratification using the recommended models, the follow-up plan can be 
estimated in a way similar to that presented in table IV [40, 71]. Regular 
monitoring is mandatory as recent studies have shown how serum 
immune markers for precursors of MM can change over time [29, 52].
Treatment
Historically, similar to MGUS, the treatment for SMM was observation. 
Older studies on SMM treatments have failed to show an OS or 
quality-of-life benefit. This was mainly due to ineffective available 
therapies and toxicities of these therapies (mainly alkylating agents). 
More modern therapies are targeted with a number of potential 
combinations which are substantially better tolerated.
Early trials
Three small studies compared early therapy with melphalan plus 
prednisone versus observation or melphalan plus prednisone 
treatment at the time of progression. These studies failed to show 
any increase in OS [89, 90].
Similarly, other trials with thalidomide and bisphosphonates failed 
to show improvement in OS and had numerous adverse events 
associated in particular with neuropathy [91], while thalidomide alone 
in SMM also proved disappointing [92].
Witzig et al. [93] presented a Phase III study of thalidomide plus 
zoledronic acid versus zoledronic acid alone in patients with SMM. 
They demonstrated that the risk of progression to active MM could 
be decreased using this combination of drugs; however, the study 
limitations were small sample size and high toxicity of the study 
drugs.
Modern approaches in SMM
The Spanish (PETHEMA) myeloma group tested lenalidomide plus 
dexamethasone for high-risk SMM (see definitions above). A total 
of 119 patients were randomized to the treatment or observation. In 
the treatment group the TTP was not met, while the median TTP 
in the observation arm was 21 months. Similarly, the 3-year OS in 
the treatment arm was higher, at 94% versus 80%. In all, 79% of 
treated patients in the induction phase and 90% in the maintenance 
phase achieved a partial response. Therefore, this treatment in early 
high-risk SMM decreased TTP and improved OS in this study [94]. 
Although this study demonstrated increased PFS and OS, the study 
had limitations as it is difficult to assess the efficacy of a combination 
treatment and the lack of accurate imaging in this study makes it 
difficult to confirm whether these patients had no myeloma-defining 
criteria. Furthermore, the median follow-up was 6 years, which was 
not a significant time to assess PFS [87].
Lonial et al. [86] compared lenalidomide versus observation in 182 
patients. In the treatment arm, response to therapy was observed in 
50% of patients, in comparison to no response in the observation arm. 
There was a significant improvement in PFS in the treatment arm in 
comparison to the observation arm (hazard ratio, 0.28; 95% CI = 0.12–
0.62; p = 0.002). Thus, they concluded that lenalidomide treatment 
delayed progression to an MDE in SMM patients. As discussed 
previously, there were several drawbacks to this study design.
Korde et al. [94] reported treatment with carfilzomib, lenalidomide, 
and dexamethasone (KRd) with lenalidomide maintenance in 
patients with high-risk SMM and newly diagnosed MM. All patients 
with SMM achieved at least a very good partial response during the 
study period. Concerning the most common of any-grade adverse 
events, 12 patients with high-risk SMM lymphopenia (12 [100%]) and 
gastrointestinal disorders (11 [92%]) were reported. A Phase III study 
is actively enrolling patients further to test this treatment on SMM 
patients [95].
Table IV. Management of smoldering multiple myeloma [40]
Plasma cell disorder Management
Low risk Annual follow-up 
Intermediate risk Monitor every 6 months 
High risk Consider clinical trial/monitor every 
2–3 months 
Early myeloma/“Ultra high-risk 
SMM”
Treat as you would treat symptomatic 
MM
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In a trial designed to potentially cure early stages of myeloma, GEM-
CESAR (NCT02415413) is a Phase II single-arm clinical trial using 
a KRd backbone for induction followed by high-dose therapy and 
autologous stem cell transplant and maintenance, essentially treating 
high-risk SMM as symptomatic myeloma. The primary endpoint of the 
study was minimal residual disease negativity rate evaluated by next-
generation flow post-induction and post-transplant. At a median of 
30 months, 93% of the patients are alive and free from progression. 
Following consolidation, the overall response rate was 100% and 
the complete response rate was 76%. The minimal residual disease 
(MRD) negativity rate following consolidation was 63%. Although 
this is a very intense treatment sequence, with a substantially higher 
response rate than lenalidomide as a single agent in the ECOG E306 
study, the 3-year PFS was similar to that reported in the E306 study. 
As a result, we must consider whether such an intense regimen is 
necessary [97].
The treatment of this disease in the absence of symptoms is a difficult 
decision. The main role of therapy in SMM is to improve OS and 
not impact the quality of life; therefore, the future of the therapeutic 
intervention in SMM may be the use of novel therapies that work 
directly on the immune system regulation and surveillance and 
maintain control of the malignant cells or treatments, which ultimately 
cure this disease at its earliest stage [72, 98].
The diagnostic and therapeutic management of MGUS, SMM, and 
MM is summarized in table V.
Future approaches to MGUS and SMM
In the future, better-defined biomarkers will be evaluated in clinical 
trials to select those patients who are at the highest risk for developing 
MDE. For example, Ghobrial et al. [99] found immune system 
dysregulation in particular natural killer cells and loss of cytotoxic T 
cells is a major contributor to the progression of MGUS and SMM. 
Furthermore, the use of chimeric antigen receptor T cells in MM has 
been shown to be an interesting target for treatment and several other 
targets are being tested [100]. At present, all SMM patients must 
undergo rigorous evaluation at initial workup to exclude subclinical 
symptomatic disease and provide risk stratification patients with 
low and intermediate risk. SMM should be closely monitored and 
potentially included in clinical studies. At present, patients with high-
risk SMM should not be treated outside of a clinical trial until we more 
precisely identify those patients who are most likely to develop MDE.
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